Table 1.

Characteristics of the patients with Alzheimer's disease before and after additional treatment.

Characteristic	Shen-Zhi-Ling group
	1st week (n)	10th week (n)	20th week (n)	25th week (n)
Age (years)	57.2 ± 9.7
Sex (M/F)	28/17
Duration of VD (years)	5.7 ± 4.9
MMSE	13.4 ± 1.8	12.9 ± 3.1	12.0 ± 2.3	11.8 ± 1.6
Huperzine A (μg/d)	323.30 ± 173.9 (32)	334.41 ± 169.3 (32)	319.29 ± 168.6 (31)	349.32 ± 188.4 (31)
Aniracetam (mg/d)	489.6 ± 179.3 (28)	491.7 ± 166.8 (28)	490.5 ± 183.4 (29)	497.6 ± 112.3 (29)
Memantine hydrochloride (mg/d)	6.67 ± 5.28 (28)	6.81 ± 4.47 (30)	6.83 ± 4.96 (29)	6.92 ± 5.67 (30)
Donepezil hydrochloride (mg/d)	8.21 ± 3.76 (16)	8.49 ± 4.02 (15)	8.73 ± 2.69 (15)	9.33 ± 6.94 (15)
Rivastigmine (mg/d)	3.38 ± 1.26 (23)	3.47 ± 1.72 (14)	3.55 ± 2.09 (13)	3.75 ± 1.66 (14)
Galantamine reminyl (mg/d)	25.89 ± 22.63 (26)	25.31 ± 23.61 (25)	25.87 ± 21.39 (26)	26.82 ± 22.91 (26)
Characteristic	Placebo group
	1st week (n)	10th week (n)	20th week (n)	25th week (n)
Age (years)	56.9 ± 10.2
Sex (M/F)	27/19
Duration of VD (years)	5.9 ± 5.2
MMSE	14.1 ± 1.5	13.3 ± 2.7	12.07 ± 3.5	11.2 ± 2.8
Huperzine A (μg/d)	358.30 ± 191.4 (34)	334.41 ± 169.3 (34)	327.03 ± 179.8 (33)	358.30 ± 191.4 (32)
Aniracetam (mg/d)	506.6 ± 108.7 (26)	498.8 ± 171.2 (25)	505.5 ± 192.3 (27)	517.2 ± 119.3 (27)
Memantine hydrochloride (mg/d)	6.71 ± 4.47 (29)	6.67 ± 5.09 (30)	6.59 ± 5.09 (29)	6.98 ± 4.47 (30)
Donepezil hydrochloride (mg/d)	8.23 ± 6.74 (14)	8.37 ± 5.33 (15)	8.66 ± 2.71 (16)	8.92 ± 7.58 (15)
Rivastigmine (mg/d)	3.45 ± 1.65 (25)	3.51 ± 1.08 (24)	3.61 ± 1.87 (25)	3.67 ± 1.72 (25)
Galantamine reminyl (mg/d)	26.12 ± 22.84 (29)	26.08 ± 21.65 (29)	25.59 ± 20.41 (29)	27.51 ± 19.66 (29)

AD: Alzheimer's disease; MMSE: Mini-Mental State Examination.